Teva sues Eli Lilly again after FDA approves migraine drug

Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly gained Food and Drug Administration (FDA) approval to market Emgality (galcanezumab-gnlm).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Awards 2026 finalists revealed

2 March 2026 Law firms, companies and individuals have been shortlisted across a range of categories, which this year include new awards for excellence in PTAB, trade secrets and medical device work.

Americas

Natera and a rival draw the line under five-year fight

27 February 2026 The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.

Americas

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

26 February 2026 As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.

More features

Gowling WLG brings in transactions expert with UK and US experience

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Wiggin’s new litigation partner deepens ‘technically complex’ offer

Could everyday hospital equipment be the next defence against counterfeit medicines?

Teva sues Eli Lilly again after FDA approves migraine drug

More on this story

Editor's picks

Editor's picks

More features